BETHESDA, Md., June 27, 2012 (GLOBE NEWSWIRE) -- Spherix Incorporated
(Nasdaq:SPEX) -- an innovator in biotechnology for therapy in diabetes,
metabolic syndrome and atherosclerosis, and provider of technical and
regulatory consulting services to food, supplement, biotechnology and
pharmaceutical companies -- today announced that Dr. Robert Lodder,
Spherix's President, will present to investors as part of the 7th LHA
Life Sciences & Medical Technologies Virtual Conference on Thursday,
June 28, 2012 at 11:30 a.m. Eastern Time. The briefing will include the
latest update on the planned SPX106T IND submission to the FDA, as well
as information on the new SPX723 and SPX100 programs. Opportunities in
aneurysm and painful bladder syndrome, new therapeutic areas for
Spherix, will also be described.

The webcast of the Spherix presentation will be accessible live and for
the next 90 days at www.spherix.com and
www.investorcalendar.com/IC/CEPage.asp?ID=168961.

This day-long virtual conference event includes 30-minute presentations
with accompanying slides from seven industry leaders, and begins at
9:00 a.m. Eastern Time.

About Spherix

Spherix Incorporated was launched in 1967 as a scientific research
company under the name Biospherics Research. The Company now leverages
its scientific and technical expertise and experience through its two
subsidiaries, Biospherics Incorporated and Spherix Consulting, Inc.
Biospherics is dedicated to developing and licensing/marketing
proprietary therapeutic products for treatment of diabetes, metabolic
syndrome and atherosclerosis. Biospherics is exploring new drugs and
combinations for treatment of high triglycerides, a risk factor for
atherosclerosis, myocardial infarction and stroke. Spherix's Consulting
subsidiary provides scientific and strategic support for suppliers,
manufacturers, distributors and retailers of conventional foods,
biotechnology-derived foods, medical foods, infant formulas, food
ingredients, dietary supplements, food contact substances,
pharmaceuticals, medical devices, consumer products and industrial
chemicals and pesticides. For more information, please visit
www.spherix.com.

Forward-Looking Statements

This release contains forward-looking statements which are made
pursuant to provisions of Section 21E of the Securities Exchange Act of
1934. Investors are cautioned that such statements in this release,
including statements relating to planned clinical study design,
regulatory and business strategies, plans and objectives of management
and growth opportunities for existing or proposed products, constitute
forward-looking statements which involve risks and uncertainties that
could cause actual results to differ materially from those anticipated
by the forward-looking statements. The risks and uncertainties include,
without limitation, risks that product candidates may fail in the
clinic or may not be successfully marketed or manufactured, we may lack
financial resources to complete development of our products, the FDA
may interpret the results of studies differently than us, competing
products may be more successful, demand for new pharmaceutical products
may decrease, the biopharmaceutical industry may experience negative
market trends, our continuing efforts to develop products may be
unsuccessful, our common stock could be delisted from the NASDAQ
Capital Market, and other risks and challenges detailed in our filings
with the U.S. Securities and Exchange Commission. Readers are cautioned
not to place undue reliance on any forward-looking statements which
speak only as of the date of this release. We undertake no obligation
to publicly release the results of any revisions to these
forward-looking statements that may be made to reflect events or
circumstances that occur after the date of this release or to reflect
the occurrence of unanticipated events.


CONTACT: Investor Relations
         Phone: (301) 897-2564
         Email: info@spherix.com